EV-302/KEYNOTE-A39
Phase III EV-302/KEYNOTE-A39: Subgroup Analyses of EV + Pembrolizumab vs Chemotherapy in Previously Untreated Adv Urothelial Carcinoma

Released: February 01, 2024

Activity

Progress
1
Course Completed